Yuan Liu

This inventor holds 29 USPTO granted patents and 18 published patent applications, plus 2 CIPO patents and 7 EPO patents, primarily in Cancer Therapeutics. Top assignees: Araxes Pharma LLC, Janssen Biotech, Inc.. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yuan Liu. Retrieved from https://idiyas.com/inventor/yuan-liu-0y4y8itg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 29 (Patent Applications = 18)

% Patents Active = 93.1

CIPO Patents = 2 (Patent Applications = 6)

EPO Patents = 7 (Patent Applications = 25)

Average Co-Inventor Count = 6.5

ph-index = 14

Forward Citations = 496(Granted Patents)

Company Filing History:

Janssen Biotech, Inc.

patents

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

Areas of Expertise:

KRAS G12C

Quinazoline Compounds

Cancer Treatment

Covalent Inhibitors

Heterocyclic Compounds

Substituted Piperazines

Benzothiophene

Fused Bicyclic Compounds

Inhibitors of RAS

Quinazoline Derivatives

Spiro Compounds

Cinnolines

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE50490 - Substituted quinazoline compounds and methods of use thereof (2025-07-15),

2. 12234244 - Substituted piperazines as inhibitors of KRAS G12C (2025-02-25),

3. 12134620 - Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer (2024-11-05),

4. 11878985 - Substituted quinazolines as inhibitors of KRAS G12C (2024-01-23),

5. 11639346 - Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS (2023-05-02),

6. 11377441 - Covalent inhibitors of KRAS (2022-07-05),

7. 11358959 - Benzothiophene and benzothiazole compounds and methods of use thereof (2022-06-14),

8. 11279689 - 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer (2022-03-22),

9. 11274093 - Fused bicyclic benzoheteroaromatic compounds and methods of use thereof (2022-03-15),

10. 11136308 - Substituted quinazoline and quinazolinone compounds and methods of use thereof (2021-10-05),

11. 11059819 - Fused hetero-hetero bicyclic compounds and methods of use thereof (2021-07-13),

12. 11021470 - 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof (2021-06-01),

13. 10975071 - Inhibitors of KRAS G12C mutant proteins (2021-04-13),

14. 10927125 - Substituted cinnolines as inhibitors of KRAS G12C (2021-02-23),

15. 10829458 - Substituted quinazoline compounds and methods of use thereof (2020-11-10),

Title: Yuan Liu: Innovator in Cancer Treatment

Introduction

Yuan Liu is a notable inventor based in San Diego, CA, with a remarkable portfolio of 28 patents. His work primarily focuses on innovative compounds designed to inhibit specific proteins that are implicated in cancer progression, particularly the G12C mutant KRAS protein.

Latest Patents

Among Yuan Liu's recent patents are two significant inventions. The first is centered on "Substituted piperazines as inhibitors of KRAS G12C." This patent describes compounds capable of modulating the activity of the G12C mutant KRAS protein, along with their pharmaceutical applications in treating various disorders, including cancer. The structure of these compounds offers potential for therapeutic efficacy in targeted cancer therapies.

The second patent involves "Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer." Similar to his prior work, this invention also focuses on inhibiting the G12C mutant KRAS protein, providing detailed methodologies linked to the preparation and application of these compounds in pharmaceutical compositions aimed at cancer treatment.

Career Highlights

Throughout his career, Yuan Liu has made significant contributions to the field of medicinal chemistry and targeted cancer therapies. He has held positions in reputable companies, including Araxes Pharma LLC and Janssen Biotech, Inc., where he applied his expertise to bridge the gap between pharmaceutical innovation and practical medical solutions.

Collaborations

Yuan Liu has collaborated with esteemed colleagues such as Liansheng Li and Pingda Ren. Their joint efforts exemplify a shared commitment to advancing research and developing effective treatments for challenging medical conditions, notably in cancer therapeutics.

Conclusion

Yuan Liu stands as a prominent figure in the field of medical inventions, particularly with his groundbreaking patents that target the G12C mutant KRAS protein involved in cancer. His work not only showcases his inventive spirit but also reflects the collaborative ethos essential in advancing medical research and innovation for the benefit of society.

Profile summary based on public USPTO records.